Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
bioinformatics; experience with (phage) virology or working with the model nematode C. elegans is a plus; the ability to work both independently and within a team; a very good command of written and oral English
-
germline sequestration in basidiomycetous fungi. The project will focus on the rise and fate of new mutations arising during the life cycle of different fungal species. The project will have a strong
-
health, and bioinformatics. You will apply advanced AI methods - from classical machine learning to large language models and agent-based AI - on large-scale healthcare datasets, including structured
-
metastatic tumors upon different therapeutic interventions. We are looking for a highly motivated Ph.D. student to join our lab and work on brain metastatic cancer. The candidate will join a young, creative
-
-derived neurons that generalize over different patients. To test candidate intervention strategies that normalize these phenotypes. In addition to these core activities, you will perform bioinformatic
-
respiration function, and how are their activities regulated? How do plants form their organs, tissues, cells and sub-cellular structures, and how is the formation of different organs and structures coordinated
-
innovative employers in the region. With more than 6000 employees from 100 different countries, we are helping to build tomorrow's world every day. Through top scientific research, we push back boundaries and
-
service-providing role in society. We are one of the largest, most international and most innovative employers in the region. With more than 6000 employees from 100 different countries, we are helping
-
most innovative employers in the region. With more than 6000 employees from 100 different countries, we are helping to build tomorrow's world every day. Through top scientific research, we push back
-
bioinformatic skills to predict the evolution of rare diseases? FSHD is a rare neuromuscular disorder. No approved treatment is currently available. Slow and variable disease progression complicate trial design